Healthcare & Health Industry Wire — Week of July 21, 2026

Neko Health raised $700 million for its preventive diagnostic model, the U.S. Food and Drug Administration (FDA) approved the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, and the Centers for Medicare & Medicaid Services (CMS) proposed lower 2027 physician-fee-schedule conversion factors. The week also brought a new $24 million voice-AI round, a five-center AmSurg acquisition in North Carolina, and a practical way for patients to use the Lipfendra news without overreading it.

Neko Health raised $700 million in a Series C co-led by Lightspeed Venture Partners and O.G. Venture Partners. The Stockholm-based company uses non-invasive, radiation-free diagnostic scans designed to capture millions of health data points, and it plans to open a New York City clinic later this year. 1

The round is a large bet on preventive screening outside a conventional hospital or primary-care visit. Neko's model depends on turning a high-volume scan into a useful clinical conversation, not simply producing more measurements. The U.S. test will be whether those measurements lead to appropriate follow-up and whether the service can fit into care pathways that already have to manage cost, referrals, and data governance.

Rime, an enterprise voice artificial intelligence company, raised $24 million in a Series A led by M13, with participation from Twilio Ventures, Corazon Capital, Unusual Ventures, and other existing investors. Fierce Healthcare reported that Rime's conversational speech models power nearly 100 million phone calls each month for customers including Mayo Clinic, Dialpad, Upstart, and Asurion. The company plans to invest in its conversational dataset and hire in engineering and research. 1

For health systems, the relevant question is where voice automation ends and clinical accountability begins. Rime's disclosed customer list points to large-scale service operations, but a voice model that handles calls still needs clear escalation rules, accurate identity and scheduling controls, and a human path for clinical questions.

The FDA approved Lipfendra (enlicitide) on July 17 as an adjunct to diet and exercise for lowering low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including people with heterozygous familial hypercholesterolemia. It is the first oral PCSK9 inhibitor; earlier PCSK9 inhibitors were injectable. 2

The approval was based on two randomized, double-blind, placebo-controlled trials involving 3,207 adults who were receiving their maximum tolerated statin dose. At week 24, LDL-C was reduced by an average of 56% more than placebo in the trial of adults with atherosclerotic cardiovascular disease or elevated cardiovascular risk, and by 59% more than placebo in the heterozygous familial hypercholesterolemia trial. 2

The FDA said adverse-event rates were similar to placebo in the first trial. In the familial-hypercholesterolemia trial, diarrhea and dizziness were more common with Lipfendra than with placebo. The release does not provide cardiovascular-event reduction data, so the approval supports LDL-C lowering, not a claim that the drug has already been shown to reduce heart attacks or strokes. 2

CMS issued its calendar year 2027 Medicare Physician Fee Schedule (PFS) proposed rule on July 14. The proposal would use two conversion factors, the dollar amounts that translate relative-value units into Medicare payment: $33.17 for qualifying Alternative Payment Model (APM) participants, down from $33.57, and $32.84 for non-qualifying APM participants, down from $33.40. CMS also described a proposed 2.50% reduction required by current law after a one-time 2026 increase expires. 3

This is a proposed rule, with most changes contemplated for January 1, 2027, not a final payment decision. Among the other proposals are paying the most expensive same-day evaluation-and-management visit or global surgical service at 100% and the other service at 50%; changing the G2211 complexity add-on into a percentage-based modifier; and creating a voluntary ACO modifier that would add 32% to certain evaluation-and-management visits for practitioners in qualifying accountable care organizations. 3

CMS is also asking for comments on restrictions to remote therapeutic monitoring, including limiting it to established patients, requiring a separately billable initiating visit, and excluding contractors from the clinical staff eligible to bill the service. That combination makes the proposal relevant to both physician groups planning 2027 budgets and technology companies whose revenue depends on remote-monitoring codes.

CMS also issued draft guidance on July 16 for how manufacturers, dispensing entities, and Part B providers would effectuate the maximum fair price for the 2028 Medicare Drug Price Negotiation Program. The comment deadline is September 18, 2026. Because the document is draft guidance, it sets an implementation framework for comment rather than a final new price. 4

Ambulatory surgery center operator AmSurg acquired five endoscopy centers in North Carolina, Becker's Hospital Review reported July 15. The centers are in the eastern and central parts of the state and provide care for acute and chronic gastrointestinal conditions. They will continue operating with AmSurg's operational, clinical, and growth support. 5

The deal comes just over a month after Ascension acquired AmSurg in a transaction valued at about $3.9 billion. AmSurg now operates more than 250 ambulatory surgery centers across 34 states, while six facilities were divested to Optum subsidiary SC Affiliates as a condition of Federal Trade Commission approval. 5

The transaction shows how a large health-system deal can be followed quickly by smaller outpatient expansion. For patients, the operating question is practical: whether physician partnerships, scheduling capacity, and local access improve after the ownership change, especially for gastrointestinal procedures that may be shifted away from hospital campuses.

The FDA approval gives patients with high LDL-C a specific question to take to a clinician: "Is my current treatment reaching the LDL-C level that is right for my risk, and would an added medicine be appropriate?" The trial population was already taking the maximum tolerated statin dose, and Lipfendra is approved as an addition to diet and exercise. 2

Before a visit, write down your current cholesterol medicines, doses, side effects, recent LDL-C results, and any history of heart or blood-vessel disease. Ask whether the new drug fits your situation and what side effects should prompt a call. Do not stop a statin, start Lipfendra, or substitute the medication for diet and exercise based on a headline or an online advertisement.

The immediate action is a medication review, not a self-directed switch. That keeps the FDA's evidence in context: Lipfendra lowers LDL-C in the studied groups, while the release does not establish a reduction in cardiovascular events.